RBC keeps target for Adams

RBC Capital Markets analyst Ken Trbovich left his 12-month price target for Adams Respiratory Therapeutics Inc. at $50 with a Sector Perform rating. He made his comments after IRI data for the four weeks ending May 21 showed a 28 basis point sequential decline in Adams' allergy medicine, Mucinex-D. RBC said the Delsym acquisition was essential as it provides another vehicle on which Adams can drive its growth over the next few years. Shares of the Chester, N.J.-based pharmaceutical company were down $0.72, or 1.50%, at $47.28 on volume of 104,547 shares versus the three-month running average of 270,000 shares. (Nasdaq: ARXT)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.